Page 2 - COPD - Training Manual - Module 4
P. 2

Synchrobreathe® : A Novel BAI












        4.1 Synchrobreathe® – introduction


        Synchrobreathe® is a BAI with a dose counter. It is a state-of-the-art innovation
        from Cipla that was launched in the year 2016. It is currently available with a
        salmeterol/fluticasone propionate combination as Seroflo, a formoterol
        /budesonide combination as Foracort, levosalbutamol as Levolin, and a
        formoterol/fluticasone combination as Maxiflo.


        Synchrobreathe® inhaler is designed to be triggered with a very low inspiratory
        flow rate ranging from approximately 23 to 35 L/min.  Hence, even young patients
        and patients with severe airflow limitation should be able to use Synchrobreathe®




        4.1.1 Design aspects

        The design of the Synchrobreathe® inhaler incorporates the ‘compactness,
        portability and ease of use’ of pMDIs with the ‘actuation on inspiration’ feature
        of DPIs.


        It comprises 23 parts that work in synchronisation to deliver a standard, uniform
        dose with just a simple inhalation by the patient (Figure 14).
   1   2   3   4   5   6   7